Last reviewed · How we verify
Intravenous acetaminophen
Intravenous acetaminophen is a Small molecule drug developed by Children's Hospital Medical Center, Cincinnati. It is currently FDA-approved. Also known as: IV Tylenol, Tylenol, OFIRMEV, Ofirmev.
At a glance
| Generic name | Intravenous acetaminophen |
|---|---|
| Also known as | IV Tylenol, Tylenol, OFIRMEV, Ofirmev |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (PHASE3)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous acetaminophen CI brief — competitive landscape report
- Intravenous acetaminophen updates RSS · CI watch RSS
- Children's Hospital Medical Center, Cincinnati portfolio CI
Frequently asked questions about Intravenous acetaminophen
What is Intravenous acetaminophen?
Intravenous acetaminophen is a Small molecule drug developed by Children's Hospital Medical Center, Cincinnati.
Who makes Intravenous acetaminophen?
Intravenous acetaminophen is developed and marketed by Children's Hospital Medical Center, Cincinnati (see full Children's Hospital Medical Center, Cincinnati pipeline at /company/children-s-hospital-medical-center-cincinnati).
Is Intravenous acetaminophen also known as anything else?
Intravenous acetaminophen is also known as IV Tylenol, Tylenol, OFIRMEV, Ofirmev.
What development phase is Intravenous acetaminophen in?
Intravenous acetaminophen is FDA-approved (marketed).
Related
- Manufacturer: Children's Hospital Medical Center, Cincinnati — full pipeline
- Also known as: IV Tylenol, Tylenol, OFIRMEV, Ofirmev
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing